IGMS Stock Price, IGM Biosciences Inc Quote, Chart

Market Summary

USD9.24-0.10

Market Closed

-1.07%

IGMS Stock Price

View Fullscreen

IGMS RSI Chart

IGMS Valuation

Market Cap

555.5M

Price/Earnings (Trailing)

-2.34

Price/Sales (Trailing)

263.88

EV/EBITDA

-2.09

Price/Free Cashflow

-2.85

IGMS Price/Sales (Trailing)

IGMS Profitability

EBT Margin

-11227.17%

Return on Equity

-146.93%

Return on Assets

-62.99%

Free Cashflow Yield

-35.03%

IGMS Fundamentals

IGMS Revenue

Revenue (TTM)

2.1M

Rev. Growth (Yr)

-4.79%

Rev. Growth (Qtr)

-23.66%

IGMS Earnings

Earnings (TTM)

-236.9M

Earnings Growth (Yr)

16.01%

Earnings Growth (Qtr)

17.92%

Breaking Down IGMS Revenue

Last 7 days

-7.9%

Last 30 days

0.9%

Last 90 days

-39.4%

Trailing 12 Months

-28.6%

How does IGMS drawdown profile look like?

IGMS Financial Health

Current Ratio

7.98

IGMS Investor Care

Shares Dilution (1Y)

35.19%

Diluted EPS (TTM)

-4.25

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.1M	0	0	0
2023	1.3M	1.6M	1.9M	2.1M
2022	0	0	0	1.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of IGM Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 29, 2024	behrens m kathleen	acquired	-	-	3,078	-
Mar 29, 2024	lee michael stewart	acquired	-	-	1,734	-
Mar 29, 2024	thompson elizabeth h.z.	acquired	-	-	1,452	-
Mar 29, 2024	redmile group, llc	acquired	-	-	1,734	-
Mar 29, 2024	topsoe jakob haldor	acquired	-	-	1,734	-
Mar 29, 2024	baker bros. advisors lp	acquired	-	-	3,988	-
Mar 29, 2024	topsoe christina teng	acquired	-	-	2,687	-
Mar 28, 2024	redmile group, llc	sold	-	-	-12,464	-
Mar 28, 2024	baker bros. advisors lp	bought	937,632	9.6194	97,473	-
Mar 27, 2024	baker bros. advisors lp	bought	257,170	9.2361	27,844	-

Which funds bought or sold IGMS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	PNC Financial Services Group, Inc.	unchanged	-	10.00	68.00	-%
May 10, 2024	GROUP ONE TRADING, L.P.	new	-	39.00	39.00	-%
May 10, 2024	ACADIAN ASSET MANAGEMENT LLC	sold off	-100	-69,000	-	-%
May 10, 2024	CITIGROUP INC	added	33.76	8,677	24,357	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	14.26	11,503	46,696	-%
May 10, 2024	DIMENSIONAL FUND ADVISORS LP	unchanged	-	52,767	380,722	-%
May 10, 2024	BlackRock Inc.	reduced	-0.59	978,219	7,314,340	-%
May 10, 2024	JPMORGAN CHASE & CO	reduced	-40.11	-24,654	56,318	-%
May 10, 2024	VANGUARD GROUP INC	reduced	-4.85	782,492	8,237,800	-%
May 09, 2024	CHARLES SCHWAB INVESTMENT MANAGEMENT INC	added	0.25	164,800	1,168,790	-%

Are Funds Buying or Selling IGMS?

Are funds buying IGMS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IGMS

No. of Funds

Unveiling IGM Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 28, 2024	baker bros. advisors lp	12.4%	4,145,706	SC 13D/A
Feb 12, 2024	price t rowe associates inc /md/	10.3%	3,403,714	SC 13G/A
Feb 12, 2024	price t rowe associates inc /md/	9.9%	3,262,209	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G
Feb 09, 2024	artal international s.c.a.	9.4%	3,100,422	SC 13G/A
Dec 15, 2023	baker bros. advisors lp	11.4%	3,744,669	SC 13D/A
Jul 19, 2023	topsoe holding a/s	31.8%	10,400,564	SC 13D/A
Jun 28, 2023	redmile group, llc	9.9%	3,291,092	SC 13D/A
Jun 28, 2023	baker bros. advisors lp	9.99%	3,277,567	SC 13D/A
Jun 13, 2023	redmile group, llc	10.3%	3,033,497	SC 13D/A

Recent SEC filings of IGM Biosciences Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 23, 2024	3	Insider Trading
Apr 17, 2024	8-K	Current Report
Apr 15, 2024	PRE 14A	PRE 14A
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading

Peers (Alternatives to IGM Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

IGM Biosciences Inc News

Latest updates

IGM Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2
Revenue	-23.7%	497,000	651,000	509,000	448,000	522,000	426,500	331,000	366,000
Operating Expenses	-17.4%	54,353,000	65,770,000	67,269,000	68,656,000	63,896,000	56,636,000	60,843,000	59,590,000
S&GA Expenses	-100.0%	-	11,580,000	12,507,000	12,983,000	13,002,000	11,619,000	12,664,000	12,372,000
R&D Expenses	-19.1%	43,815,000	54,190,000	54,762,000	55,673,000	50,894,000	45,017,000	48,179,000	47,218,000
EBITDA Margin	2.8%	-108	-111	-123	-141	-166	-201	-	-
Income Taxes	-100.0%	-	242,000	240,000	109,000	87,000	-	-	-
Earnings Before Taxes	17.6%	-49,816,000	-60,453,000	-61,749,000	-64,314,000	-59,222,000	-52,576,000	-58,037,000	-58,595,000
EBT Margin	2.7%	-112	-115	-127	-146	-171	-206	-	-
Net Income	17.9%	-49,816,000	-60,695,000	-61,989,000	-64,423,000	-59,309,000	-52,576,000	-58,037,000	-58,595,000
Net Income Margin	2.7%	-112	-115	-127	-146	-171	-206	-	-
Free Cashflow	9.2%	-44,901,000	-49,456,000	-43,204,000	-57,018,000	-54,934,000	-40,553,000	-43,124,000	109,484,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																				(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Assets	-11.2%	376	423	474	481	463	513	541	582	258	298	332	351	380	409	212	229	243	261	270	-
Current Assets	-12.9%	303	348	398	402	385	438	480	522	198	241	268	290	341	373	185	201	213	231	248	2.00
Cash Equivalents	-29.6%	79.00	113	175	151	140	121	177	221	75.00	133	166	246	252	241	27.00	32.00	48.00	36.00	194	2.00
Net PPE	-2.4%	37.00	38.00	37.00	38.00	37.00	33.00	32.00	31.00	30.00	28.00	28.00	27.00	26.00	23.00	14.00	10.00	5.00	4.00	3.00	1.00
Liabilities	-2.4%	215	220	220	222	223	226	213	207	53.00	53.00	47.00	28.00	25.00	27.00	24.00	22.00	19.00	21.00	15.00	9.00
Current Liabilities	-10.7%	38.00	42.00	43.00	44.00	44.00	45.00	44.00	36.00	27.00	28.00	20.00	19.00	15.00	17.00	13.00	11.00	8.00	9.00	6.00	9.00
Shareholder's Equity	-20.7%	161	203	254	259	239	287	328	375	205	245	286	322	356	382	188	207	224	240	255	-
Retained Earnings	-6.1%	-871	-821	-760	-698	-634	-574	-522	-464	-405	-353	-303	-258	-220	-188	-163	-143	-124	-107	-92.39	-64.07
Additional Paid-In Capital	0.8%	1,032	1,024	1,014	957	873	862	851	840	610	598	588	581	575	570	352	350	348	347	347	1.00
Shares Outstanding	14.9%	60.00	52.00	50.00	45.00	44.00	42.00	44.00	44.00	34.00	33.00	33.00	33.00	33.00	31.00	31.00	31.00	30.00	9.00	4.00	0.00
Float	-	-	-	-	132	-	-	-	219	-	-	-	664	-	-	-	514	-	265	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	11.6%	-42,417	-48,008	-40,121	-53,105	-50,997	-37,858	-40,413	111,307	-38,889	-35,300	-34,406	-27,014	-28,262	-23,342	-15,075	-13,077	-16,387	-12,067	-15,380	-9,324	-8,345
Share Based Compensation	-14.2%	7,922	9,237	11,954	14,309	11,047	11,109	10,816	11,286	11,499	8,548	6,212	5,609	5,504	2,582	2,594	1,955	1,323	400	334	141	139
Cashflow From Investing	158.9%	8,651	-14,693	19,549	-6,325	69,824	-18,811	-3,748	-183,982	-19,103	2,240	-47,110	20,720	39,611	21,228	11,485	-2,953	28,529	-143,727	-58,363	-433	-715
Cashflow From Financing	-62.2%	152	402	44,639	69,952	75.00	482	297	218,531	72.00	1,491	1,071	-33.00	-53.00	215,910	-917	-234	22.00	-1,994	224,650	49,569	10,033

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

IGMS Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Collaboration revenue	$ 497	$ 522
Operating expenses:
Research and development	43,815	50,894
General and administrative	10,538	13,002
Total operating expenses	54,353	63,896
Loss from operations	(53,856)	(63,374)
Other income (expense):
Interest income	4,040	4,172
Other expense	0	(20)
Total other income (expense)	4,040	4,152
Loss before income tax expense	(49,816)	(59,222)
Income tax expense	0	(87)
Net loss	$ (49,816)	$ (59,309)
Net loss per share, basic	$ (0.83)	$ (1.33)
Net loss per share, diluted	$ (0.83)	$ (1.33)
Weighted-average common shares outstanding, basic	60,114,409	44,466,764
Weighted-average common shares outstanding, diluted	60,114,409	44,466,764

IGMS Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 79,173	$ 112,520
Restricted cash	325	592
Marketable securities	214,595	225,157
Prepaid expenses and other current assets	8,660	9,328
Total current assets	302,753	347,597
Property, plant and equipment, net	37,300	38,232
Operating lease right-of-use assets	34,474	35,773
Other non-current assets	1,605	1,809
Total assets	376,132	423,411
Current liabilities:
Accounts payable	3,995	1,326
Accrued liabilities	23,652	31,544
Lease liabilities	6,628	5,834
Deferred revenue	3,655	3,777
Total current liabilities	37,930	42,481
Lease liabilities, non-current	34,300	34,672
Deferred revenue, non-current	142,649	143,024
Total liabilities	214,879	220,177
Commitments and contingencies (Note 5)
Stockholders' equity:
Preferred stock, $0.01 par value; 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Additional paid-in-capital	1,031,850	1,023,739
Accumulated other comprehensive loss	(128)	151
Accumulated deficit	(871,058)	(821,242)
Total stockholders' equity	161,253	203,234
Total liabilities and stockholders' equity	376,132	423,411
Common Stock Class Undefined
Stockholders' equity:
Common stock, value	335	331
Non-voting Common Stock
Stockholders' equity:
Common stock, value	$ 254	$ 255

About IGM Biosciences Inc

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's product candidate, including imvotamab (IGM-2323), an IgM-based CD20 x CD3 bispecific antibody T cell engager that is in Phase 2 clinical trials for the treatment of B cell non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1a/1b clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody that is in Phase 1 clinical trials for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

CEO	Mr. Fred M. Schwarzer J.D.
WEBSITE	https://igmbio.com
INDUSTRY	Biotechnology
EMPLOYEES	289

IGM Biosciences Inc Frequently Asked Questions

What is the ticker symbol for IGM Biosciences Inc? What does IGMS stand for in stocks?

IGMS is the stock ticker symbol of IGM Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of IGM Biosciences Inc (IGMS)?

As of Mon May 13 2024, market cap of IGM Biosciences Inc is 555.46 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IGMS stock?

You can check IGMS's fair value in chart for subscribers.

What is the fair value of IGMS stock?

You can check IGMS's fair value in chart for subscribers. The fair value of IGM Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of IGM Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IGMS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is IGM Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether IGMS is over valued or under valued. Whether IGM Biosciences Inc is cheap or expensive depends on the assumptions which impact IGM Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IGMS.

What is IGM Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, IGMS's PE ratio (Price to Earnings) is -2.34 and Price to Sales (PS) ratio is 263.88. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IGMS PE ratio will change depending on the future growth rate expectations of investors.